Genentech sues Biogen for debt over blockbuster MS drug

Published Date: 08 Mar 2023

Roche's Genentech Inc sued Biogen MA Inc in federal court in San Francisco, alleging that Biogen owed additional patent royalties from worldwide sales of its blockbuster multiple sclerosis and Crohn's disease drug, Tysabri.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

For incarcerated people, study shows gaps exist in quality of cancer care

2.

How a California Oncologist Making $850k Spends Money

3.

The most precise research tools for the deadliest blood cancer have been developed.

4.

Blinatumomab Plus Chemotherapy New Standard for Children With B-Cell ALL

5.

Big PFS Increase in Advanced Neuroendocrine Tumors With Combination Therapy


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot